In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins.
The influence of intravenous infusions of various prostaglandins on in vivo platelet function was studied after labelling of autologous platelets with 100 mu ci 111 indium-oxinesulfate in patients with peripheral vascular disease stage II according to FONTAINE. PGI2 (5 ng/kg/min) provoked a significant decrease of platelet deposition and a prolongation in platelet half-life time (74 +/- 6 vs 68 +/- 5 hours). PGE1 (25 ng/kg/min) failed to influence platelet deposition, but prolonged significantly platelet half-life time (82 +/- 6 vs 76 +/- 8 hours). CG 4203 (25 ng/kg/min) decreased significantly platelet deposition and prolonged significantly platelet half-life time (73 +/- 10 vs 67 +/- 11 hours). Iloprost (1 and 2 ng/kg/min) reduced significantly platelet deposition without dose relation. Half-life time was increased significantly after therapy compared to placebo (1 ng: 76 +/- 7 vs 69 +/- 7; 2 ng: 73 +/- 9 vs 67 +/- 9 hours).
Fitscha
P
P
2nd Department of Internal Medicine, University of Vienna, Austria.
Kaliman
J
J
O'Grady
J
J
Sinzinger
H
H
D000368:Aged; D000527:Alprostadil / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology*; D002317:Cardiovascular Agents / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology* / Q000031:analogs & derivatives; D006801:Humans; D016285:Iloprost; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*
D002317:Cardiovascular Agents; D010975:Platelet Aggregation Inhibitors; C039188:taprostene; D011464:Epoprostenol; D000527:Alprostadil; D016285:Iloprost